

ONWARD Announces End of Quiet Period and Participation in Upcoming Scientific Conferences

EINDHOVEN, the Netherlands & LAUSANNE, Switzerland—December 1, 2021--ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announces that its research partners will provide contributions to the following scientific conferences in December 2021.

Professor G. Courtine, Ph.D. and Jocelyne Bloch, M.D. will speak at the [Global Summit – Hello Tomorrow](#) event in Paris, France, 2-3 December 2021, a gathering of thought leaders from the Deep Tech community. Professor Courtine is neuroscientist at the Swiss Federal Institute of Technology Lausanne (EPFL) and Dr. Bloch is a neurosurgeon at the University Hospital Lausanne (CHUV). Together, they founded NeuroRestore, a center dedicated to the development of neurotherapies that is principally devoted to restoring movement and other functions in people with spinal cord injury. They also co-founded ONWARD, which won the first edition of the Hello Tomorrow Challenges. Professor Courtine and Dr. Bloch will speak as part of the Summit's "Healthcare Revolutions" track.

In addition, Professor Courtine will deliver a keynote address entitled, "Kinésithérapeute 2.0", at the Journée Dijonnaise de la Kinésiologie, a leading event devoted to identifying and discussing emerging trends in physiotherapy. This event will be held in Dijon, France, on 4 December 2021.

Lastly, ONWARD has now reached the end of its statutory post-IPO quiet period, effective 01 December 2021. *"The quiet period is required by regulation and is intended to allow a stock to become established in the financial markets following an initial public offering," said Dave Marver, ONWARD's CEO. "With its expiration, we are pleased to begin sharing more frequent updates about our progress and activities."*

About ONWARD

ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury. ONWARD's work builds on more than a decade of basic science and preclinical research conducted at the world's leading neuroscience laboratories. ONWARD's ARC Therapy, which can be delivered by implantable (ARC^{IM}) or external (ARC^{EX}) systems, is designed to deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. ONWARD has received three Breakthrough Device Designations from the FDA encompassing both ARC^{IM} and ARC^{EX}. The company's first FDA pivotal trial, called Up-LIFT, commenced in January 2021 with plans to enroll 65 subjects at up to 15 centers worldwide.

ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands. It maintains an office at the EPFL Innovation Park in Lausanne, Switzerland and has a growing U.S. presence in Boston, Massachusetts, USA. For additional information about the company, please visit ONWD.com.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, SOUTH-AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

For Company Enquiries:

ONWARD

info@onwd.com

For Media and Investor Enquiries:

Backstage Communication

Gunther De Backer

Tel: +32 (0)475 903 909

gunther@backstagecom.be

Disclaimer

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.